Stockscreener 앱 받기
5.125
2.92%
0.155
전일 마감가:
$4.97
열려 있는:
$5
하루 거래량:
481.51K
Relative Volume:
0.41
시가총액:
$306.67M
수익:
-
순이익/손실:
$-44.80M
주가수익비율:
-6.8333
EPS:
-0.75
순현금흐름:
$-30.67M
1주 성능:
+13.16%
1개월 성능:
+69.37%
6개월 성능:
+7.01%
1년 성능:
+18.95%
1일 변동 폭
$4.9425
$5.18
1주일 범위
$4.435
$5.18
52주 변동 폭
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.12 | 259.35M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.82 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.61 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.43 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.92 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.52 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
What makes Aldeyra Therapeutics Inc. stock price move sharplyCapital Safe Smart Trades - Newser
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
How Aldeyra Therapeutics Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
(ALDX) Trading Report - news.stocktradersdaily.com
Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny Stocks - simplywall.st
Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - simplywall.st
Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha
Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN
Aldeyra Therapeutics (ALDX) Gets a Buy from JonesTrading - The Globe and Mail
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma | ALDX Stock News - GuruFocus
Aldeyra receives FDA special protocol assessment for lymphoma drug - Investing.com
PFG Investments LLC Sells 295,997 Shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Defense World
When the Price of (ALDX) Talks, People Listen - news.stocktradersdaily.com
Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease - HCPLive
Aldeyra resubmits NDA for dry eye disease drug after trial success - Investing.com
Aldeyra resubmits NDA for dry eye disease drug after trial success By Investing.com - Investing.com South Africa
Aldeyra Therapeutics (ALDX) Resubmits FDA Application for Dry Ey - GuruFocus
Aldeyra resubmits Reproxalap's marketing application to FDA - Seeking Alpha
Aldeyra Therapeutics Resubmits New Drug Application For Dry Eye Drug; Shares Up Pre-Bell - MarketScreener
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application f - GuruFocus
Aldeyra (ALDX) Resubmits Drug Application for Dry Eye Treatment to FDA | ALDX Stock News - GuruFocus
Aldeyra Resubmits Reproxalap NDA to FDA - TipRanks
Aldeyra's Dry Eye Drug Hits Major Trial Goal (P=0.002), FDA Application Resubmitted After Previous Rejection - Stock Titan
Aldeyra Therapeutics Holds Annual Meeting with Key Votes - TipRanks
Trend Tracker for (ALDX) - news.stocktradersdaily.com
June 2025's Spotlight On Promising Penny Stocks - simplywall.st
Two Sigma Investments LP Sells 15,349 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
161,926 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Purchased by Millennium Management LLC - Defense World
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Mackenzie Financial Corp Purchases 36,160 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
BNP Paribas Financial Markets Trims Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Bank of America Corp DE Reduces Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
ProShare Advisors LLC Acquires Shares of 14,031 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Two Sigma Advisers LP Sells 84,000 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Trading (ALDX) With Integrated Risk Controls - news.stocktradersdaily.com
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference | ALDX Stock News - GuruFocus
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - Business Wire
Northern Trust Corp Purchases 16,894 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Acquired by Deutsche Bank AG - Defense World
D. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs - Defense World
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - Yahoo Finance
HC Wainwright Has Strong Forecast for ALDX FY2029 Earnings - Defense World
Q2 EPS Estimate for Aldeyra Therapeutics Lifted by Analyst - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Raised to “Sell” at StockNews.com - Defense World
Balyasny Asset Management L.P. Acquires New Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Given “Buy” Rating at HC Wainwright - Defense World
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.05%
1.95%
자본화:
|
볼륨(24시간):